相似文献
1
Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylate.
Rheumatology (Oxford). 2016 Oct;55(10):1916-8. doi: 10.1093/rheumatology/kew245. Epub 2016 Jun 23.
2
Systemic capillary leak syndrome following bosentan treatment in a patient with systemic sclerosis.
Scand J Rheumatol. 2019 Sep;48(5):426-427. doi: 10.1080/03009742.2019.1584641. Epub 2019 Apr 23.
3
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis.
Expert Rev Clin Immunol. 2020 Sep;16(9):931-942. doi: 10.1080/1744666X.2020.1813569. Epub 2020 Oct 3.
4
Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
J Cancer Res Ther. 2014 Oct-Dec;10(4):1107-8. doi: 10.4103/0973-1482.146095.
5
Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Indian J Pharmacol. 2016 Jul-Aug;48(4):458-459. doi: 10.4103/0253-7613.186214.
6
Hypertrophic osteoarthropathy with imatinib therapy.
Intern Med J. 2015 Oct;45(10):1088-90. doi: 10.1111/imj.12858.
7
A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
Expert Opin Drug Saf. 2016;15(4):571-8. doi: 10.1517/14740338.2016.1152258. Epub 2016 Feb 27.
8
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
JAMA Oncol. 2015 May;1(2):143-4. doi: 10.1001/jamaoncol.2015.50.
9
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Cancer Chemother Pharmacol. 2015 Dec;76(6):1185-9. doi: 10.1007/s00280-015-2905-6. Epub 2015 Nov 6.
10
Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma.
J Am Acad Dermatol. 2001 Feb;44(2):312-3. doi: 10.1067/mjd.2001.110643.
引用本文的文献
1
Diuretic-Resistant Ascites Following Laparoscopic Surgery in a Patient With Chronic Myeloid Leukemia on Imatinib Therapy.
Cureus. 2021 Feb 4;13(2):e13127. doi: 10.7759/cureus.13127.
2
Successful Treatment of Sjögren's Syndrome Presenting as a Condition Similar to Chronic Capillary Leak Syndrome Using Combination Therapy with High-Dose Intravenous Immunoglobulin and Glucocorticoid.
Case Rep Rheumatol. 2019 Mar 4;2019:4865024. doi: 10.1155/2019/4865024. eCollection 2019.
本文引用的文献
1
Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
Arthritis Res Ther. 2015 Aug 18;17(1):213. doi: 10.1186/s13075-015-0721-3.
2
Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.
Sci Transl Med. 2013 May 29;5(187):187ra69. doi: 10.1126/scitranslmed.3005066.
3
Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Semin Arthritis Rheum. 2013 Feb;42(4):377-90. doi: 10.1016/j.semarthrit.2012.06.001. Epub 2012 Jul 11.
4
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Nat Med. 2006 Aug;12(8):908-16. doi: 10.1038/nm1446. Epub 2006 Jul 23.
5
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
Cancer Res. 2001 Apr 1;61(7):2929-34.
6
Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis.
Arthritis Rheum. 1999 May;42(5):930-41. doi: 10.1002/1529-0131(199905)42:5<930::AID-ANR11>3.0.CO;2-1.
7
Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.
Science. 1997 Jul 11;277(5323):242-5. doi: 10.1126/science.277.5323.242.
8
A novel physiological function for platelet-derived growth factor-BB in rat dermis.
J Physiol. 1996 Aug 15;495 ( Pt 1)(Pt 1):193-200. doi: 10.1113/jphysiol.1996.sp021584.
Zotero 插件